AgainChance focus on γ9δ2 T cells, the most abundant subset of γδ T cells in peripheral blood. γ9δ2 T cells recognize transformed cells in a HLA-unrestricted manner. These cells respond to markers of cellular stress, such as isopentenyl pyrophosphate (IPP) which is produced in high quantity by transformed cells through the mevalonate pathway. A number of Phase I trials have demonstrated that these cells can be safely employed in cancer immunotherapy of lymphoid and solid tumors.

We have developed a method to robustly expand γ9δ2 T cells to clinical relevant numbers with less than 30 ml of blood in 15 days, and are exploring the use of these cells in combination with other established approached to improve therapeutic outcome of cancer treatment.

Instead, due to the lack of graft versus host disease effect, γ9δ2 T cells will be used as vector cells of our off-the-shelf TCR-redirected T cell therapy.